[[(2R,3S,4R,5R)-5-[6-(6-azidohexylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [[(2R,3S,4R,5R)-5-[6-(6-azidohexylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• 化学式: C16H27N8O13P3
• 分子量: 632.4
• InChiKey: SXEGAVBMZIOWPW-XNIJJKJLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  40
• 可旋转键数：
  16
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  280
• 氢给体数：
  7
• 氢受体数：
  19

文献信息

• Modification of 3′ terminal ends of nucleic acids by DNA polymerase theta
  申请人：Temple University-Of The Commonwealth System of Higher Education

  公开号：US10865396B2

  公开（公告）日：2020-12-15

  The invention provides compositions and methods for modifying the 3′-terminal ends of nucleic acids using DNA polymerase θ terminal transferase activity.

  本发明提供了利用 DNA 聚合酶 θ 末端转移酶活性修饰核酸 3′-末端的组合物和方法。
• DNA polymerase theta mutants, methods of producing these mutants, and their uses
  申请人：INSTITUT PASTEUR

  公开号：US11384345B2

  公开（公告）日：2022-07-12

  The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.

  本发明涉及能够进行非模板核酸延伸的 Pol theta 亚家族的突变 DNA 聚合酶或这种聚合酶的功能片段、生产这些突变 DNA 聚合酶的方法、使用这些突变 DNA 聚合酶的试剂盒和方法。
• MODIFICATION OF 3' TERMINAL ENDS OF NUCLEIC ACIDS BY DNA POLYMERASE THETA
  申请人：Temple University Of The Commonwealth System Of Higher Education

  公开号：EP3368692A1

  公开（公告）日：2018-09-05
• DNA POLYMERASE THETA MUTANTS, METHODS OF PRODUCING THESE MUTANTS, AND THEIR USES
  申请人：Institut Pasteur

  公开号：EP3684946A1

  公开（公告）日：2020-07-29
• Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP
  申请人：NESBITT Natasha M.

  公开号：US20140170689A1

  公开（公告）日：2014-06-19

  The present invention provides a recombinant polypeptide comprising a first portion and a second portion, wherein the sequence of the first portion is fully identical to amino acids 1 to 248 of the sequence set forth as SEQ ID NO:1 and the sequence of the second portion is other than amino acids 249 to 511 of the sequence set forth as SEQ ID NO:1.